GlaxoSmithKline Pharmaceuticals Limited has disclosed receiving a significant court decree in a legacy case that dates back over two decades. The pharmaceutical company informed stock exchanges about the development on December 18, as part of its regulatory disclosure obligations.

Court Decree Details

The Court of Small Causes, Bombay issued a decree on May 6, which the company received on November 2. The case pertains to mesne profits for office premises that were formerly used by Burroughs Wellcome (India) Limited prior to its merger with GlaxoSmithKline Pharmaceuticals.

Case Background and Timeline

The decree relates to a matter that is more than 24 years old, concerning office premises formerly occupied by Burroughs Wellcome (India) Limited before its merger with the company. GlaxoSmithKline Pharmaceuticals explained that the delayed intimation occurred because the company did not have any record of this case, making it difficult to immediately confirm whether it was attributable to them.

The total financial impact includes the original mesne profit amount of ₹87.09 lakhs plus accumulated simple interest at 9% per annum from June 2001, bringing the total demand to ₹37.19 crores.

Company Response and Next Steps

GlaxoSmithKline Pharmaceuticals has indicated that it is currently evaluating the court decree and will take appropriate actions, including filing an appeal in due course to mitigate any potential impacts. The company has assured stakeholders that it will pursue all available legal remedies to address the matter.

Regulatory Compliance

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company filed the disclosure with both BSE Limited and The National Stock Exchange of India Limited on December 18, ensuring compliance with mandatory reporting requirements for material developments that could impact the company's operations or financial position.

GlaxoSmithKline Pharmaceuticals Limited has disclosed receiving a GST demand order from Bihar Central GST authorities, marking a regulatory development that requires investor attention. The pharmaceutical company received the order on 12 December 2025, though the order itself was dated 11 November 2025.

GST Demand Details

The demand order issued by the Assistant Commissioner, CGST CX, Patna Central Division pertains to FY2021-22 and involves GST credit-related issues. The total demand breakdown is presented below:

Nature of Alleged Violation

The GST authorities have raised the demand in relation to GST credit-related issues, specifically citing mismatches between the company's GST returns and details reported by suppliers. This type of discrepancy typically arises when there are differences in the input tax credit claims made by the company versus the corresponding output tax declarations by their suppliers in the GST system.

Company's Response and Impact Assessment

GlaxoSmithKline Pharmaceuticals has indicated that the demand order will have no impact on the company's financial operations. The management has stated that they are currently evaluating the demand order and will take appropriate actions in due course. This suggests the company may either contest the demand through available legal remedies or seek clarification on the alleged discrepancies.

Regulatory Compliance

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company communicated the development to both BSE Limited and The National Stock Exchange of India Limited on 12 December 2025, ensuring compliance with mandatory disclosure requirements for material events that could impact investor decisions.